BrightPath Biotherapeutics Co., Ltd. (4594.T)
JPY 46.0
(-2.17%)
JPY 46.0
(-2.17%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 251.26 Million JPY | 87.65% |
| 2022 | 133.9 Million JPY | -44.14% |
| 2021 | 239.72 Million JPY | 13.19% |
| 2020 | 211.78 Million JPY | -11.54% |
| 2019 | 239.4 Million JPY | 14.88% |
| 2018 | 208.39 Million JPY | -26.97% |
| 2017 | 285.33 Million JPY | 37.74% |
| 2016 | 207.15 Million JPY | 32.29% |
| 2015 | 156.58 Million JPY | -22.99% |
| 2014 | 203.33 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 151.19 Million JPY | -39.83% |
| 2023 Q3 | 655.82 Million JPY | 337.07% |
| 2023 FY | 251.26 Million JPY | 87.65% |
| 2023 Q4 | 251.26 Million JPY | -61.69% |
| 2023 Q1 | 115.65 Million JPY | -13.63% |
| 2023 Q2 | 150.04 Million JPY | 29.74% |
| 2022 Q4 | 133.9 Million JPY | -9.19% |
| 2022 Q3 | 147.45 Million JPY | 33.38% |
| 2022 Q2 | 110.55 Million JPY | -24.97% |
| 2022 Q1 | 147.34 Million JPY | -38.54% |
| 2022 FY | 133.9 Million JPY | -44.14% |
| 2021 Q1 | 170.63 Million JPY | -19.43% |
| 2021 Q2 | 164.77 Million JPY | -3.43% |
| 2021 Q3 | 175.02 Million JPY | 6.22% |
| 2021 FY | 239.72 Million JPY | 13.19% |
| 2021 Q4 | 239.72 Million JPY | 36.97% |
| 2020 Q2 | 189.69 Million JPY | 15.47% |
| 2020 Q3 | 185.13 Million JPY | -2.4% |
| 2020 Q4 | 211.78 Million JPY | 14.39% |
| 2020 FY | 211.78 Million JPY | -11.54% |
| 2020 Q1 | 164.27 Million JPY | -31.38% |
| 2019 Q3 | 243.67 Million JPY | 39.84% |
| 2019 FY | 239.4 Million JPY | 14.88% |
| 2019 Q1 | 160.78 Million JPY | -22.85% |
| 2019 Q4 | 239.4 Million JPY | -1.75% |
| 2019 Q2 | 174.25 Million JPY | 8.38% |
| 2018 Q2 | 222.7 Million JPY | 1.75% |
| 2018 Q1 | 218.86 Million JPY | -23.29% |
| 2018 Q3 | 186.38 Million JPY | -16.31% |
| 2018 Q4 | 208.39 Million JPY | 11.81% |
| 2018 FY | 208.39 Million JPY | -26.97% |
| 2017 Q4 | 285.33 Million JPY | 19.16% |
| 2017 FY | 285.33 Million JPY | 37.74% |
| 2017 Q1 | 151.79 Million JPY | -26.72% |
| 2017 Q2 | 224.33 Million JPY | 47.78% |
| 2017 Q3 | 239.44 Million JPY | 6.74% |
| 2016 Q2 | 148.67 Million JPY | -3.53% |
| 2016 Q1 | 154.11 Million JPY | -1.58% |
| 2016 FY | 207.15 Million JPY | 32.29% |
| 2016 Q4 | 207.15 Million JPY | 7.09% |
| 2016 Q3 | 193.43 Million JPY | 30.11% |
| 2015 Q4 | 156.58 Million JPY | -34.62% |
| 2015 Q3 | 239.5 Million JPY | 14.18% |
| 2015 Q2 | 209.76 Million JPY | 0.0% |
| 2015 FY | 156.58 Million JPY | -22.99% |
| 2014 FY | 203.33 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 92.261% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -296.255% |
| GNI Group Ltd. | 26.34 Billion JPY | 99.046% |
| Linical Co., Ltd. | 10.3 Billion JPY | 97.562% |
| Trans Genic Inc. | 3.81 Billion JPY | 93.409% |
| MEDINET Co., Ltd. | 590.2 Million JPY | 57.427% |
| Soiken Holdings Inc. | 697.02 Million JPY | 63.951% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 91.682% |
| AnGes, Inc. | 2.78 Billion JPY | 90.992% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | 51.078% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.722% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | 28.874% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 84.771% |
| Carna Biosciences, Inc. | 472.35 Million JPY | 46.805% |
| CanBas Co., Ltd. | 91.98 Million JPY | -173.154% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 77.024% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 68.973% |
| Chiome Bioscience Inc. | 593.73 Million JPY | 57.68% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 94.093% |
| PeptiDream Inc. | 29.11 Billion JPY | 99.137% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | 55.645% |
| Ribomic Inc. | 155.8 Million JPY | -61.267% |
| SanBio Company Limited | 2.25 Billion JPY | 88.857% |
| Healios K.K. | 11.28 Billion JPY | 97.774% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | 31.905% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -4.046% |
| StemRIM | 187 Million JPY | -34.368% |
| CellSource Co., Ltd. | 677.73 Million JPY | 62.925% |
| FunPep Company Limited | 189.32 Million JPY | -32.719% |
| Kringle Pharma, Inc. | 596.95 Million JPY | 57.908% |
| Stella Pharma Corporation | 1.44 Billion JPY | 82.594% |
| TMS Co., Ltd. | 97.68 Million JPY | -157.213% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -174.629% |
| Cuorips Inc. | 200.96 Million JPY | -25.034% |
| K Pharma,Inc. | 209.13 Million JPY | -20.147% |
| Takara Bio Inc. | 11.42 Billion JPY | 97.8% |
| ReproCELL Incorporated | 741.03 Million JPY | 66.092% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 72.62% |
| StemCell Institute Inc. | 3.85 Billion JPY | 93.474% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 72.34% |
| CellSeed Inc. | 301.04 Million JPY | 16.535% |